www.thecolumngroup.com Open in urlscan Pro
97.74.184.17  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content
 * Home
 * Team
 * Portfolio
 * News
   * TCG News
   * Portfolio News
 * Careers
 * Contact

Menu
 * Home
 * Team
 * Portfolio
 * News
   * TCG News
   * Portfolio News
 * Careers
 * Contact

extraordinary
starts here
TCG is a science-driven venture capital firm with $3.5 billion in assets under
management. TCG's funds are invested in a select group of early stage drug
discovery companies with unique scientific platforms that can change the world.

The Column Group (TCG) is a science-driven venture capital firm that makes
significant financial and operational commitments to build early stage drug
discovery companies based on their unique scientific platforms and potential to
deliver multiple breakthrough therapeutics.

TCG’s investment strategy takes the long view in company building, recognizing
that significant time is often required to generate significant value. Our
approach is not “building-to-exit.” Key variables, including scientific
opportunities, the competitive and regulatory landscape, and Pharma priorities,
can change very rapidly. Instead, TCG’s mission is the generation of
fundamentally strong companies, built from the ground up, based on great science
and the ability to generate a robust pipeline.

Our investments are focused around early stage drug discovery as the best source
of a new generation of novel, highly effective human therapies. We believe that
the most critical resources, such as great ideas, world-class founders, and top
quality managerial and scientific talent, are very rare and that concentrating
them within a small cohort of companies is key to success. TCG is about the bold
pursuit of big ideas; our companies use innovative science to discover
breakthrough therapies that address significant diseases. Our firm brings
together a rich combination of scientific, financial, and operational expertise
to build and support a valuable portfolio of companies poised to have a profound
impact on human health.

The Column Group is a ‘big science, dare-to-dream’ venture fund. They identify
large, unmet needs in life sciences and back these ideas and teams with
conviction.

Bill Rieflin, Executive Chairman, NGM



TCG’s success starts with idea generation, having the capacity and connections
across the scientific community to generate at least the germ of a powerful idea
in-house. That’s not something you find everywhere.

Richard Heyman, CEO, Aragon, Seragon & ORIC



The driving force behind TCG is great science and the desire to start meaningful
companies with a key platform component that will be here for the long term.

Terry Rosen, CEO, Flexus & Arcus



The Column Group is a visionary venture firm with a passion for investing in
innovative approaches to important unmet needs. They understand that solving big
problems requires big ideas and rigorous science, and their commitment to the
success of their companies is second to none.

Nancy Thornberry, CEO, Kallyope



Contact Us
Investor Login

Copyright © 2022. The Column Group | Privacy Policy | Terms of Use
Website developed by CP Communications

Linkedin
Scroll to Top